Andy Ambrose Joins MassMutual's Institutional Sales Team for Retiremen... ( SPRINGFIELD Mass. Nov. 15 /- Andy...)

Andy Ambrose Joins MassMutual's Institutional Sales Team for Retirement Services

Date:11/15/2007

SPRINGFIELD, Mass., Nov. 15 /PRNewswire/ -- Andy Ambrose has joined the MassMutual Retirement Services Division's institutional sales team reporting to David Test, division sales manager. Ambrose is based in Texas and supports MassMutual's third party distribution channel relationships in the south Texas region.

He joins MassMutual from John Hancock where he most recently served as regional vice president for the company's retirement plan services business. Ambrose has more than 13 years as a successful retirement plan wholesaler including positions at The Hartford's PLANCO and Retirement Plan Divisions.

"Our growing momentum can only be strengthened by the addition of Andy's energy, sales skills and passion to our winning team," states Bill O'Grady, senior vice president and head of national sales and distribution for MassMutual's Retirement Services Division.

Ambrose can be contacted at aambrose@massmutual.com or (512) 573-5000. For more information about MassMutual Retirement Services, please call (888) 626-4911.

Photos available upon request from lreilly@massmutual.com

Contact: Lisa Reilly

413-744-0589

lreilly@massmutual.com

SOURCE MassMutual Retirement Services Division
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:11/9/2009)...v. 9 Sutter Health, a family of do...are service providers, is donating $255,000 to foo...ocal food banks will share the quarter-million-dol...tables of thousands of families across the north s...partnering with and supporting charitable programs...

(Date:11/9/2009)...s with drugs that inhibit estrogen, , ,... to treat breast cancer and osteoporosis eliminate...y. , The drugs also cleared precancerous growth...t of cancer in mice with precancerous lesions. ,...t cancer/osteoporosis drug raloxifene were given t...

(Date:11/9/2009)... both eye conditions are age-related, researchers ...-- Cataract surgery doesn,t appear to speed the pr...), according to a new study that challenges the be...s the other. , "Because both conditions are str...also have AMD," wrote Li Ming Dong, of Stony Brook...

(Date:11/9/2009)...9 /PRNewswire-FirstCall/ - Hard To Treat Diseases ...hat Novartis, a US$41 billion international health...1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmac... Switzerland will begin a five-year, $1 billion Ch...matically increase its investment in its China R&a...

(Date:11/9/2009)...sive Cancer Network (NCCN) has posted a draft whit...radigm for near-term comparative effectiveness cli...cument introduces the NCCN Comparative Therapeutic...ompares the risk-versus-benefit of different treat...tice Guidelines in Oncology(TM). The paper will be...

Breaking Medicine News(10 mins):Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2 Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2 Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2 Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2 Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3 Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4 Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2 Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3 Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4

[0] Sutter Health Donates $255,000 to Help the Hungry This Holiday Season [0] Breast Cancer Drugs May Fight Cervical Cancer, Too [0] Cataract Surgery Doesn't Worsen Macular Degeneration: Study [2] Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million [0] NCCN Posts Comparative Effectiveness White Paper for Public Comment

...hiladelphia, PA, June 25, 2007 State policies hav...y substance abuse treatment programs, and could pl...arch-based "comprehensive" treatment approaches, r...licy proscriptions emanating from scientific resea...

...tem cell research and the potential use of human e...oversial issue which splits both scientific and pu...stem cells throughout the world deals particularly...t. It is a symbolic struggle over the whole future...

...y dose of rivaroxaban cut risk of venous thromboem... (HealthDay News) -- Extended use of the oral drug... clots after hip replacement surgery, British res.... Current guidelines recommend patients receive a ...

...ARBOR, Mich., June 25 HealthMedia(R), Inc.,s,Succ...o-year Health,Information Products (HIP) Certifica...ance (NCQA), the most trusted source for informati...A, since responsibility for adherence to NCQA HRA ...

...cal Division Officer says " ... when we used Jelly...patients from the painful burning and stinging ...act.", SAVANNAH, Ga., June 25 Captain Kevin Carv...at provided,any true relief until he tried Jellyfi...

...R KNOLLS, N.J., June 25 MedeFile,International, I...zing in,portable electronic medical records manage...usive, membership only, resort community located i...ting of over 1,400 members., Members who subscrib...

Other Medicine News:Health News:State policies influence drug treatment programs 2 Health News:Stem cell research from an ethical point of view 2 Health News:Oral Drug Helps Prevent Clotting After Hip Replacement 2 Health News:HealthMedia Health Risk Assessment Earns Prestigious NCQA Certification 2 Health News:Okaloosa Island Fire Department Will Use Jellyfish Squish to Treat Jellyfish Stings 2 Health News:Okaloosa Island Fire Department Will Use Jellyfish Squish to Treat Jellyfish Stings 3 Health News:Exclusive Resort Community Looks to MedeFile to Provide Members With Access to Medical Records Anytime, Anywhere 2

State policies influence drug treatment programs Stem cell research from an ethical point of view Oral Drug Helps Prevent Clotting After Hip Replacement HealthMedia Health Risk Assessment Earns Prestigious NCQA Certification Okaloosa Island Fire Department Will Use Jellyfish Squish to Treat Jellyfish Stings Exclusive Resort Community Looks to MedeFile to Provide Members With Access to Medical Records Anytime, Anywhere

(Date:11/9/2009)...RMINGHAM, Ala., Nov. 9 S...at it will host an investor conference call at 11:... to discuss its 2009 third quarter operating resul...ly an hour following the conclusion of the confere...gi-bin/prnh/20080812/CLTU111LOGO ) ,, Please...

(Date:11/9/2009)...DFORD, Mass., Nov. 9 Hol... ), a leading developer, manufacturer and supplier...nd surgical products dedicated to serving the heal... for the fourth quarter and fiscal year ended Sept...ed the Board of Directors has promoted Robert Casc...

(Date:11/9/2009)...ENWOOD, Ill., Nov. 9 La...n personal and environmental radiation monitoring ...quisitions in accordance with its long-term strate...the acquisitions of Global Physics Solutions, Inc....ll Saxelby, President and CEO of Landauer. "These ...

[0] Surgical Care Affiliates Announces Investor Conference Call to Discuss 2009 Third Quarter Results [0] Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results [0] Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market

...7 /PRNewswire/ -- Expression,Genetics, Inc., annou...udy evaluating the Company,s lead drug candidate,...f Alabama at,Birmingham and , evaluated the safety...activity of the EGEN-001 in 13 patients,with advan...ct,utilizing the Company,s proprietary TheraPlas(...

...fect on QTc Interval, HAYWARD, Calif., April 16, 2... today presented safety data from,preclinical and ...spimycin (KOS-953). Serial electrocardiogram (ECG)...e 1 trials of tanespimycin.,Cardiac monitoring ana...espimycin was found to have no effect on QTc inter...

Other Medicine Technology:Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 2 Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 3 Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 4 Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 2 Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 3 Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 4

Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR

Vitreoretinal Viscodissector 45 degrees

Infusion Cannula 6mm

Lacrimal Intubation Tubing

Replacment Tubing

Medicine Products:

Vitreoretinal Viscodissector 45 degrees Infusion Cannula 6mm Lacrimal Intubation Tubing Replacment Tubing

Andy Ambrose Joins MassMutual's Institutional Sales Team for Retiremen...( SPRINGFIELD Mass. Nov. 15 /- Andy...),Health